ASH 2017 | An introduction into the PATHEMA trial
Bruno Paiva, PhD of the University of Navarra, Pamplona, Spain, talks about the results of the PATHEMA trial, a phase 3 clinical trial for newly diagnosed transplant-eligible multiple myeloma (MM) patients, presented at ASH 2017.
Paiva explains that there were two abstracts presented at ASH 2017 which spoke about this clinical trial. One focused on the efficacy of induction therapy and the toxicity. The other focused on the impact in terms of patient outcomes about MRD assessment, using next generation flow for the first time in a perspective fashion.
Recorded at the American Society of Hematology Annual Meeting 2017, held in Atlanta, GA.
Get great new content delivered to your inboxSign up